Rosetta Genomics Posts Q3 Revenues of $136K, Seeks $2.5M in Private Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported third-quarter revenues of $136,000, compared to no revenues for the comparable period of 2009.

The Rehovot, Israel-based developer of microRNA-based diagnostic products has three tests on the market and is preparing to launch next-generation versions of those tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.